"If the pharmaceutical industry had developed a single drug capable of reducing cancer mortality by 25%, autoimmune disorders by 39%, and COVID-19 infection rates by 74%, it would be heralded as a miracle drug,"
The 2025 immunization guidelines marked a shift from quadrivalent to trivalent influenza vaccines, introduced new RSV timing protocols, and revised multiple vaccination schedules, including meningococcal B dosing for ages 16-23 years.
COVID-19 was associated with a myocarditis rate of 0.73 per 1,000 person-years compared to 0.24 for influenza, with young males showing the highest rates.